Lilly Validates Gene Editing Space With $1.3B Verve Buy, But Analysts Are Skeptical

Eli Lilly is set to acquire Verve Therapeutics for up to $1.3 billion, including $1 billion upfront in cash ($10.50/share) and a contingent value right (CVR) of $3/share tied to the first patient dosing of VERVE-102 in a Phase III trial. The deal, representing a 113% premium to Verve’s 30-day average, aims to bolster Lilly's portfolio of genetic medicines focused on cardiovascular risk and has spurred a rally in gene editing stocks like Intellia, Beam, and Editas; however, some analysts question the commercial need for new genetic medicines in common conditions given existing oral and siRNA therapies.

Analysis

Eli Lilly's definitive agreement to acquire Verve Therapeutics for up to $1.3 billion, comprising $1 billion in upfront cash ($10.50 per share) and a $3 per share contingent value right (CVR), marks a significant development in the gene editing sector. The CVR is tied to the first patient dosing in a Phase III trial of VERVE-102, a base editing therapy for atherosclerotic cardiovascular disease (ASCVD), within ten years of deal closure. This transaction, representing a 113% premium to Verve's 30-day average closing price, has catalyzed a positive sentiment across the gene editing space, evidenced by premarket gains in Intellia Therapeutics (12% to $10.10), Beam Therapeutics (nearly 7% to $17.75), and Editas Medicines (over 4% to $2.25). Lilly's acquisition aims to bolster its pipeline with genetic medicines targeting common cardiovascular conditions, a departure from traditional rare disease applications for gene editing, with Verve's lead asset VERVE-102 (targeting PCSK9 for HeFH) currently in Phase Ib trials. Analyst opinions are divergent: BMO Capital Markets questions the commercial necessity of gene editing in indications with existing oral (Merck, AstraZeneca) and siRNA therapies and suggests potentially better capital allocation for Lilly. Conversely, William Blair views the deal as a 'bargain' for Lilly, strategically sound given the existing licensing agreement for VERVE-102 (with an opt-in decision due by year-end), and anticipates the CVR payout with a Phase III trial initiation for VERVE-102 projected for the first half of 2027. This acquisition provides a much-needed 'vote of confidence' to the gene therapy field, which has recently faced setbacks such as a patient death linked to Sarepta Therapeutics' Elevidys and adverse events in an Intellia trial.

Key Decisions for Investors

• Investors should monitor the broader gene editing sector (e.g., NTLA, BEAM, EDIT) for potential re-rating and increased M&A interest following Lilly's validation, while remaining cognizant of the inherent clinical development risks highlighted by recent adverse events.
• Eli Lilly (LLY) shareholders should view this acquisition as a strategic, albeit relatively small, foray into the potentially transformative field of gene editing for prevalent cardiovascular diseases, balancing the long-term vision against analyst concerns regarding near-term commercial competition and optimal capital deployment.
• For Verve Therapeutics (VERV) investors, the acquisition provides a substantial upfront premium and a clear path to realizing additional value through the CVR, contingent on successful clinical progression of VERVE-102.
• Consider the competitive landscape for VERVE-102, including established oral therapies from Merck and AstraZeneca and approved siRNA treatments, as a key factor influencing its future market penetration and commercial success, despite its 'one-and-done' treatment potential.